Do you really understand hyaluronic acid? Comprehensive interpretation

Date: September 13, 2023 Categories: Industry News Views: 869

1 Hyaluronic acid

1.1 Introduction to hyaluronic acid

Hyaluronic acid, also known as hyaluronic acid, referred to as HA (hyaluronic acid), has a molecular formula of (C14H21NO11)n. It is a macromolecular mucopolysaccharide composed of D-glucuronic acid and N-acetylglucosamine. It is widely present in the connective tissue and extracellular matrix of animals and humans, such as: joint cavity, skin, vitreous body, cartilage, umbilical cord and other tissues. It has strong viscoelasticity and hygroscopicity, and is an important component of the extracellular matrix. It has unique functions such as hydration, moisturizing, and lubrication, and can also repair cells. The sodium salt compound of hyaluronic acid is stable in nature, so sodium hyaluronate is often used. The hyaluronic acid often mentioned in cosmetics is sodium hyaluronate.

2 Development history and origin of hyaluronic acid[2]

2.1 Development history

Early development: In 1934, Karl Meyer, a professor of ophthalmology at Columbia University in the United States, and others first isolated a new raw material that can hold moisture, moisturize and lubricate from the vitreous body of bovine eyes, and named it "hyaluronic acid", which is later commonly known as "hyaluronic acid". However, the production process at that time was mainly based on animal tissue extraction, which was expensive and more than ten times more expensive than gold, which to a certain extent limited the application of hyaluronic acid.

Rapid development period: In 1985, the Japanese cosmetics company Shiseido successfully adopted the microbial culture method to prepare hyaluronic acid, which greatly reduced the production cost of hyaluronic acid and made large-scale production possible, greatly broadening the application scenarios of hyaluronic acid and accelerating the development of the hyaluronic acid industry.

Stable development period: Since 2010, the production process of hyaluronic acid has gradually matured and taken another step forward. The emergence of hyaluronic acid derivatives such as cationic HA, enzyme-cut low-molecular HA, and acetylated HA has made hyaluronic acid more widely used in various fields. Hyaluronic acid for different purposes differs in preparation technology, purification method, product performance, etc.

2.2 Source of hyaluronic acid

Animal tissue extraction method: mainly derived from chicken combs and vitreous body of pigs, cattle, and sheep, etc., but the raw material source is limited, the extraction cost is high, the yield is low, and the selling price is very expensive.

Microbial fermentation method: mainly using glucose, yeast powder, etc. as raw materials, obtained through fermentation and purification process. This type of hyaluronic acid can set the molecular weight according to commodity demand, with low production cost and controllable quality. It is the current mainstream production process.

Synthesis method: hyaluronic acid is synthesized through enzyme polymerization reaction, but it has disadvantages such as impurity and is currently only in the laboratory research and development stage.

3 Application and preparation of hyaluronic acid

3.1 Application of hyaluronic acid

Balazs is known as the father of HA medical application research. He divides the application of HA into five major aspects, namely viscoelastic supplementation therapy, viscoelastic filling, viscoelastic surgery, viscoelastic barrier, and viscoelastic protection[2].

Viscoelastic supplementation: HA injection as a viscoelastic supplementation treatment for osteoarthritis is one of the most successful medical applications of HA. This therapy uses HA solution to supplement or replace synovial fluid under pathological conditions, and improves the physiological environment of the diseased joint by restoring the viscoelasticity of the synovial fluid, reducing friction, and improving joint mobility, thereby reducing pain and promoting the healing of intra-articular injuries.

Viscoelastic filling: HA gel is used to fill and expand the skin, sphincter, vocal cords, and pharyngeal connective tissue to improve defects in the filled area. Most HA soft tissue fillers are cosmetic fillers based on chemically cross-linked HA to prolong the degradation time in the body. This type of product can effectively correct nasolabial folds, fill wrinkles on the forehead, around the eyes, around the mouth, etc., and can also correct tear trough deformities, plump lips, plump earlobes, etc.

Viscoelastic surgery: In 1979, the first HA ophthalmic viscoelastic (OVD) product was successfully used in cataract surgery. During surgery, HA can be used to support the operating space (maintain the depth of the anterior chamber) and protect corneal endothelial cells or other tissues from mechanical damage. In addition, HA is also used in arthroendoscopic surgery, ear surgery, and endoscopic mucosal resection.

Viscoelastic barrier: refers to the use of HA to isolate adjacent tissues to prevent postoperative adhesions and reduce scar formation. The most common use is to prevent postoperative adhesions after abdominal and pelvic surgeries. In addition, HA's viscoelastic barrier therapy has been extended to otolaryngology, filling the nasal cavity or ear space to isolate the mucosal surface, prevent adhesions, and control surgical bleeding.

Viscoelastic protection: refers to the use of HA solution to protect the tissue surface from dehydration and damage by harmful substances, and promote the healing of surface trauma. In eye protection, HA is a component of human tears. HA solution with viscoelasticity can reduce eye discomfort and relieve visual fatigue. It has a good effect on the treatment of dry eyes and can also increase the comfort of wearing contact lenses.

3.2 Preparation of hyaluronic acid[1]

For commercial hyaluronic acid products, molecular weight is an important quality parameter. Different hyaluronic acid end products have strict and differentiated requirements for the molecular weight of hyaluronic acid.

  1. Preparation technology of high molecular weight hyaluronic acid (2,400-2,600 kDa, 3,000-3,500 kDa, 3,500-4,000 kDa)

The technical points for preparing high molecular weight hyaluronic acid include: producing high molecular weight hyaluronic acid in the fermentation stage, the technical difficulty lies in the selection of strains, culture medium and the setting of production process parameters; in the separation and purification stage, the damage to the molecular weight should be reduced as much as possible, the technical difficulty lies in the selection of process and the control of process parameters. High molecular weight hyaluronic acid (such as more than 2,000 kDa) has better viscoelasticity, cohesion and film-forming properties, and is suitable for medical products such as ophthalmic viscoelastics.

  1. Low molecular weight hyaluronic acid preparation technology (2-5 kDa, 5-10 kDa, 30-50 kDa, 200-400 kDa)

Degradation is a common technology for preparing low molecular weight hyaluronic acid using high molecular weight hyaluronic acid. Oligomeric hyaluronic acid (molecular weight less than 10 kDa) has the characteristics of high absorption rate and is easy to penetrate into the dermis. It has the functions of promoting damage repair and providing cell protection, and has broad medical and cosmetic application prospects. There are three main types of hyaluronic acid degradation methods: physical degradation, chemical degradation and biodegradation.

Ø It is difficult to reduce hyaluronic acid to below 10 kDa by physical degradation;

Ø Oligomeric hyaluronic acid prepared by chemical degradation requires more intense reaction conditions, which has certain damage to the chemical structure of the obtained oligomeric hyaluronic acid, reduces biological activity, and the production process will pollute the environment;

Ø Enzymatic degradation of hyaluronic acid will not destroy its chemical structure, and the reaction conditions are mild, which will not cause environmental pollution, and is most suitable for the preparation of oligomeric hyaluronic acid.

3.3 Hyaluronic acid modification

Due to the poor stability of natural HA, its sensitivity to hyaluronidase and free radicals, its short retention time in the body, and its lack of mechanical strength in water systems, unmodified natural HA is easily degraded and absorbed in the body due to the presence of hyaluronidase and free radicals. Its retention time in the skin, eyes, joints, and other parts of the body ranges from about 1 to 21 days[6].

For hyaluronic acid used in viscoelastic supplementation or viscoelastic filling therapy, it is necessary to modify the hyaluronic acid structure to make the hyaluronic acid molecules more stable, thereby slowing down its degradation rate in the body and prolonging its duration of action.

Currently, the main method for structural modification of hyaluronic acid is cross-linking. Cross-linking is a chemical conjugation reaction that connects some functional groups in the hyaluronic acid macromolecules with a certain chemical substance to obtain a polymer gel with a three-dimensional conformation. After cross-linking, the hyaluronic acid has a dense network structure. The conventional cross-linking method is to stir and mix hyaluronic acid and a cross-linking agent in an aqueous solution, and use the cross-linking agent to chemically bond the hyaluronic acid polymer chains to prepare it.

Common crosslinking agents include divinyl sulfone (DVS) and 1,4-butanediol diglycidyl ether (BDDE). The crosslinking agent content is an important indicator for sodium hyaluronate testing. Excessive content may lead to certain safety issues. For details, please refer to YY/T 0962-2014 "Cross-linked Sodium Hyaluronate Gel for Plastic Surgery". The standard recommends the use of gas phase method and microplate reader detection method to determine the crosslinking agent content. The gas phase method is simple and quick to operate, and the microplate reader detection method has higher specificity [7].

4 Overview of domestic sodium hyaluronate approval [8]

According to the "Medical Device Classification Catalog" issued by NMPA, there are three types of sodium hyaluronate materials. This article only discusses injectable fillers for plastic surgery.

Ø13 Passive implantable devices-09 Plastic and general surgical implants-02 Plastic injection fillers

Ø14 Injection, care and protection devices-08 Absorbable surgical dressings (materials)-02 Absorbable surgical anti-adhesion dressings

Ø16 Ophthalmic devices-07 Ophthalmic implants and auxiliary devices-04 Ocular viscoelastics

5 Overview of sodium hyaluronate market[8]

According to a report by research firm Frost & Sullivan, the global hyaluronic acid raw material market sales reached 600 tons in 2020, with a compound annual growth rate of 14.4% from 2016 to 2020. It is expected that the global hyaluronic acid raw material market will maintain a high compound annual growth rate of 14.9% in the next five years, and sales will increase to 1,223 tons in 2025.

Hyaluronic acid raw materials can be divided into pharmaceutical grade, cosmetic grade and food grade according to their use and technical requirements. The main industry barriers are reflected in technology. Medical grade hyaluronic acid has the highest requirements for quality and purity, followed by cosmetic grade, and finally food grade.

1) Food grade (48.3% in 2019): Food grade hyaluronic acid is mainly used in various nutritional supplements and health products, and is widely used in developed countries in Europe and the United States. According to Frost & Sullivan data, the compound growth rate of food grade hyaluronic acid raw materials from 2015 to 2019 was 24.5%, which was significantly higher than cosmetic grade and medical grade, and the sales volume accounted for a continuous increase.

Studies have shown that oral hyaluronic acid has the effects of replenishing water, improving joint function and osteoporosis, repairing gastric mucosal damage, promoting wound healing, improving the cardiovascular system, improving rickets symptoms, improving human immunity, and promoting angiogenesis.

2) Cosmetic grade (47.8% in 2019): Cosmetic grade hyaluronic acid is mainly used in various moisturizing skin care products, makeup and daily chemical products, and the protein content is strictly controlled. Before 2019, the production share remained above 45%, the highest share. The compound growth rate of cosmetic grade is expected to reach 14.9% from 2019 to 2024E, leading other categories.

The water retention of hyaluronic acid is one of its most important physiological functions, and its theoretical water retention value is as high as 500ml/g or more. Compared with other commonly used moisturizers, hyaluronic acid is less affected by environmental humidity, with high moisture absorption at low relative humidity (33%) and low moisture absorption at high relative humidity (75%).

3) Pharmaceutical grade (4% in 2019): Strict production requirements and the highest product added value: Pharmaceutical grade hyaluronic acid has the most stringent quality control. When companies produce pharmaceutical grade hyaluronic acid, they need to undergo GMP (Good Manufacturing Practice) quality audits and stability tests, and also need pharmaceutical factory production licenses, drug approval numbers, etc. The whole process generally takes 2-5 years. But on the other hand, in terms of price and profitability, pharmaceutical grade products are also significantly higher than other categories.

According to the research report of Industrial Securities, the formal regulatory market: from 2015 to 2020, under the admission price, the scale of China's hyaluronic acid market increased from 1.88 billion yuan to 5.09 billion yuan, with a CAGR of +22.0%; it is expected to be about 12.04 billion yuan in 2024, and the CAGR is predicted to be +24.0% from 2020 to 2024.

1) Import: Huadong Medicine's South Korean LG Yiwan, Allergan's Juvederm and Galderma's Restylane occupy the top three in sales; among them, Yiwan occupies 22% of the market share with high cost performance, surpassing the old brand Juvederm to rank first;

2) Domestic: The hyaluronic acid products of domestic brands Aimei, Huaxi and Haohai Biotechnology still have room for improvement in quality compared with imported products, and the market positioning is mid-to-low-end; among them, Aimei's Hi-body occupies 26% of the market sales due to its differentiated positioning for neck lines and the scarcity of licenses.

6 Representative manufacturers of hyaluronic acid products

6.1 Bloomage Biotechnology[9]

Founded in 2000, Bloomage Biotechnology relies on two core technologies: microbial fermentation to produce hyaluronic acid and microbial enzymatic cleavage to produce low molecular weight hyaluronic acid on a large scale. It mainly produces pharmaceutical-grade, cosmetic-grade and food-grade hyaluronic acid raw materials and is currently the world's largest supplier of hyaluronic acid raw materials. It was listed on the A-share Science and Technology Innovation Board on November 6, 2019. As of March 15, 2022, the company's market value is RMB 49.34 billion. The price-earnings ratio is 63.07.

Bloomage Biotechnology's medical terminal product business mainly includes soft tissue fillers such as hyaluronic acid injections, medical skin wound protectants, ophthalmic viscoelastics, and bone and joint cavity injection injections.

In 2019, Huaxi Bio's annual sales were 1.886 billion yuan, and its net profit attributable to the parent company after deducting non-recurring items was 586 million yuan; in 2020, the company's revenue was 2.633 billion yuan, a year-on-year increase of 39.61%, and its net profit attributable to the parent company after deducting non-recurring items was 645 million yuan, a slight year-on-year increase. In 2020, the company's gross profit margin was 81.41%. In 2021, the company's annual operating income was 4.948 billion yuan, a year-on-year increase of 87.93%, and its net profit attributable to the parent company after deducting non-recurring items was 782 million yuan.

Revenue overview of each business end in 2021:

Raw materials: The company achieved sales of approximately 286.10 tons of hyaluronic acid raw materials throughout the year, with a production capacity of 470 tons and sales revenue of 905 million yuan, a year-on-year increase of 28.62%, accounting for 18.29% of the company's main business revenue. The overall gross profit margin of the raw material business was 72.19%, and the gross profit margin of pharmaceutical-grade hyaluronic acid raw materials remained at a high level of 87%. The sales of pharmaceutical-grade, cosmetic-grade, and food-grade HA were 252 million, 391 million, and 108 million, respectively, up 15.82%, 15.98%, and 36.85% year-on-year.

Medical terminals: In 2021, the company achieved revenue of 700 million yuan, up 21.54% year-on-year, accounting for 14.15% of the company's main business revenue; the gross profit margin was 82.05%. Skin medical products achieved revenue of 504 million yuan, up 15.88% year-on-year; orthopedic injection products achieved revenue of 123 million yuan, up 37.08% year-on-year; other products achieved a total revenue of 72 million yuan, up 42.70% year-on-year.

Functional skin care products: In 2021, the company achieved revenue of 3.32 billion yuan, up 146.57% year-on-year, higher than the growth rate of the same period last year. The gross profit margin was 78.98%, down 2.90 percentage points from the same period last year. Among them, the core brand Runbaiyan had a revenue of 1.229 billion yuan, a year-on-year increase of 117.42%; Quadi had a revenue of 979 million yuan, a year-on-year increase of 150.19%; Mibeier had a revenue of 420 million yuan, a year-on-year increase of 111.12%; BioMeso had a revenue of 1.229 billion yuan, a year-on-year increase of 117.42%;435 million, a year-on-year increase of 286.21%;

6.2 Aimeikang [10]

Aimeike was established on June 9, 2004, and was listed on the A-share Growth Enterprise Market on September 28, 2020. As of February 19, 2022, the company's market value was RMB 96.71 billion, with a price-earnings ratio of 102.32. In 2009, it became the first domestic company to obtain a Class III medical device registration certificate for injectable sodium hyaluronate skin fillers approved by the National Medical Products Administration.

The company's products are mainly aimed at plastic surgery, cosmetic surgery, dermatology and other departments of medical institutions. The injectable sodium hyaluronate series products are injected into the face and neck by trained doctors to repair wrinkles and sunken tissues; the polydioxanone facial implant products are implanted into the subcutaneous fat layer by trained doctors to provide support for the superficial fat, thereby improving nasolabial wrinkles.

In 2021, the company's operating income was 1.448 billion yuan, and its net profit attributable to the parent company was 958 million yuan, a year-on-year increase of 117.81%; the net profit attributable to the parent company after deducting non-recurring items is expected to be 914 million yuan, a year-on-year increase of 115.55%. Among them, solution injection products were 1.046 billion yuan, gel injection products were 385 million yuan, facial implants were 5 million yuan, and cosmetics were 11 million yuan.

The "Hi-body" series of products are still the company's revenue support. According to the company's announcement, the revenue of solution injection products (mainly "Hi-body") in the first half of 2021 accounted for 75%, a year-on-year increase of 230.38%. At present, "Hi-body" has successfully become a well-known domestic brand with the only Class III device certificate for neck wrinkle indications and excellent results.

"Rubai Angel" was approved in June 21 and was launched in July 21. The milky white filler containing ingredients such as poly-L-lactic acid microspheres can be directly injected without compounding. It is a new generation of shaping products that activates its own collagen regeneration, achieving immediate and lasting shaping effects. It combines the biggest advantages of ordinary hyaluronic acid and baby face needles on the market. While improving the shape, it can also achieve light and shadow brightening, visually guaranteeing the shaping effect.

In February 2020, Aimeikang established a joint venture company, Dongfang Meike (Beijing) Technology Development Co., Ltd., with DongBang Medical Co., Ltd. of South Korea, to engage in the research and development and production of implants and suture instruments, further expanding the research and clinical application of facial implants, and has completed the laboratory stage development of the second-generation products.

At present, the "botulinum toxin type A for injection" co-developed by Aimeikang has entered Phase III clinical trials, and the "liraglutide injection" product for chronic weight management has completed Phase I clinical trials.

6.3 Allergan [11]

Allergan Inc. was established in 1950 and is headquartered in Irvine, California, USA. It is a multi-professional health care company. In 2020, pharmaceutical giant AbbVie acquired Allergan for US$63 billion. Allergan products are widely used in the central nervous system, eye care, medical cosmetology and dermatology, gastroenterology, women's health, urology and anti-infection treatment. The annual gross profit margin basically remains above 80%.

The most well-known product is the injectable botulinum toxin type A, Botox (commonly known as the "face-lifting injection"). Botox is the world's largest botulinum toxin market share product, and its global share once reached 86%, and it currently remains above 65%. In addition, its hyaluronic acid injection filler Juvederm also ranks first in the world. In 2019, the revenue of medicine/medical beauty/ophthalmology accounted for 48%/26%/17% of the total revenue respectively. In Allergan's medical beauty sector, Botox and Juvederm contributed more than 50% of the revenue in total, and they have continued to grow after more than ten years of listing. In 2019, the revenue of Botox medical beauty/Juvederm was US$1.66 billion/US$1.24 billion, accounting for 39%/29% of the medical beauty revenue respectively.

References:

[1] Source: Huaxi Biotechnology Prospectus

[2] Yao Li. The past and present of hyaluronic acid [J]. China Cosmetics, 2021(S1):6-8.

[3] Wei Jian, Liu Jianjian, Huang Siling, Li Man, Li Xia, Guo Xueping. Research progress of cross-linked hyaluronic acid derivatives [J]. Polymer Materials Science and Engineering, 2017, 33(10):183-190.DOI:10.16865/j.cnki.1000-7555.2017.10.032.

[4] Arianna Fallacara. Erika Baldini, Stefano Manfredini and Silvia Vertuani, Hyaluronan acid in the Third Millennium. Polymers 2018, 10, 701

[5] Source: https://entokey.com/hyaluronic-acid-and-other-soft-tissue-fillers-for-facial-rejuvenation/

[6] Hyaluronic Acid in the Third Millennium. Polymers 2018, 10, 701

[7] Fu Haiyang, Yu Hao, Li Min, Jiang Aili, Fu Bufang, Wang Zhaoxu. Research on the detection method of crosslinker content in the industry standard "Cross-linked Sodium Hyaluronate Gel for Plastic Surgery" [J]. Beijing Biomedical Engineering, 2021, 40(03): 288-294.

[8] Industrial Securities - Medical Beauty Industry Investment Framework - Looking for Allergan in China's Medical Beauty

[9] Source: Huaxi Biotechnology Company's official website and public information

[10] Source: Aimei's official website and public information

[11] Source: Public information and announcement information from Guoyuan Securities and Allergan

[12] Source: Allergan announcement and Guoyuan Securities

FacebookXRedditPinterestLinkedIn